We found that LOXL2 is highly expressed in gemcitabine-resistant pancreatic cancers compared to the gemcitabine-sensitive by examining both pancreatic patients and pancreatic cancer cells. This evidence concerns the gene LOXL2 and pancreatic neoplasm.